Passage Bio Receivables 2020-2025 | PASG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Passage Bio receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Passage Bio receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.9B
Amgen (AMGN)	$155B
Gilead Sciences (GILD)	$141.4B
Vertex Pharmaceuticals (VRTX)	$99.8B
Bristol Myers Squibb (BMY)	$96.9B
GSK (GSK)	$81.3B
CSL (CSLLY)	$67.8B
Regeneron Pharmaceuticals (REGN)	$62.2B
Alnylam Pharmaceuticals (ALNY)	$59.5B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$28.4B
BioNTech SE (BNTX)	$24.8B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.6B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.9B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.7B
Exelixis (EXEL)	$10.4B
Moderna (MRNA)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.8B
Halozyme Therapeutics (HALO)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.2B